Equities researchers at Zacks Research lifted their Q4 2024 earnings estimates for Sarepta Therapeutics in a research note issued to investors on Monday, February 3rd. Zacks Research analyst S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback